Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study.

abstract：:The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography...

journal_title：Cancer chemotherapy and pharmacology

authors： Bressolle F,Jacquet JM,Galtier M,Jourdan J,Donadio D,Rossi JF

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:As reported, epidermal growth factor receptor (EGFR) is over expressed in a variety of cancers including esophageal squamous cell carcinoma. Therefore, it becomes one of the potential targets for treating esophageal cancer. Pingyangmycin (PYM), a single A5 component of bleomycin, is currently used for the treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Gong JH,Liu XJ,Li Y,Zhen YS

更新日期：2012-05-01 00:00:00

abstract：PURPOSE:To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS:Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three pat...

journal_title：Cancer chemotherapy and pharmacology

authors： Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D,Gentet JC,Bracard S,André N

更新日期：2015-08-01 00:00:00

abstract：:The intestinal absorption of 6-mercaptopurine and its nucleoside 6-mercaptopurine riboside has been studied in the rat with the in situ dual luminal and vascular perfusion. 6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity. V...

journal_title：Cancer chemotherapy and pharmacology

authors： Pennington AM,Bronk JR

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Transcatheter arterial chemoembolization (TACE) causes damage to liver function and decreases the activity of cytochrome P450 in patients with hepatocellular carcinoma (HCC). But there was no report on whether the activity of Phase II conjugating enzymes was affected in HCC patients after TACE treatment. The pu...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Jia Y,Liu X,Liu L,Wang Q,Wen A

更新日期：2010-01-01 00:00:00

abstract：PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients. METHODS:A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogene...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasuga A,Hamamoto Y,Takeuchi A,Kawasaki K,Suzuki T,Hirata K,Sukawa Y,Takaishi H,Kanai T

更新日期：2017-03-01 00:00:00

abstract：PURPOSE:Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as...

journal_title：Cancer chemotherapy and pharmacology

authors： Amato R,Stepankiw M,Gonzales P

更新日期：2013-06-01 00:00:00

abstract：PURPOSE:Abiraterone acetate (AA) was recently approved for castration-resistant prostate cancer in Japan. Two phase 1 studies were conducted to assess the pharmacokinetics of abiraterone after single-dose administration in Japanese healthy men and to evaluate the effects of food timing on abiraterone pharmacokinetics a...

journal_title：Cancer chemotherapy and pharmacology

authors： Inoue K,Shishido A,Vaccaro N,Jiao J,Stieltjes H,Bernard A,Yu M,Chien C

更新日期：2015-01-01 00:00:00

abstract：:In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed after other chemotherapy. PTT was scheduled by escalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tura S,Mazza P,Gherlinzoni F,Zinzani PL,Poletti G,Visani G,Lemoli RM,Cavo M,Galieni P,Tassi C

更新日期：1989-01-01 00:00:00

abstract：:The pharmacokinetics of soluble oral prednisolone were studied during induction therapy in six children with acute lymphoblastic leukaemia. There was a three- to four-fold variation in the pharmacokinetics of total and free prednisolone. For total prednisolone, the mean elimination half-life was relatively short (1.37...

journal_title：Cancer chemotherapy and pharmacology

authors： Choonara I,Wheeldon J,Rayner P,Blackburn M,Lewis I

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND:Adjuvant chemotherapy is gaining an increasing role in resectable gastric cancer. Customizing chemotherapy on the basis of chemosensitivity may improve outcome, and putative predictive molecular markers have been mostly evaluated in Asian patients. We profiled key DNA and damage signaling factors and correla...

journal_title：Cancer chemotherapy and pharmacology

authors： De Dosso S,Zanellato E,Nucifora M,Boldorini R,Sonzogni A,Biffi R,Fazio N,Bucci E,Beretta O,Crippa S,Saletti P,Frattini M

更新日期：2013-07-01 00:00:00

abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...

journal_title：Cancer chemotherapy and pharmacology

authors： Zylicz Z,Wagener DJ,Fernandez del Moral P,van Rennes H,Wessels JM,Winograd B,van der Kleijn E,Vree TB,van Haelst U,van den Broek LA

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Valproic acid (VPA), a widely used antiepileptic, also inhibits histone deacetylase (HDAC), and is undergoing evaluation as an anti-cancer agent. We studied the pharmacokinetics of VPA in the plasma and cerebrospinal fluid (CSF) in a non-human primate model that is highly predictive of human CSF penetration to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Thompson PA,Ou CN,Berg SL,McGuffey L,Gibson B,Blaney SM

更新日期：2008-04-01 00:00:00

abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

journal_title：Cancer chemotherapy and pharmacology

authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Clinical data suggested that a regimen incorporating doxorubicin to 5-fluorouracil (5-FU) and cisplatin may be more effective but probably quite toxic for advanced gastric cancer patients. With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, ci...

journal_title：Cancer chemotherapy and pharmacology

authors： Cascinu S,Galizia E,Labianca R,Ferraù F,Pucci F,Silva RR,Luppi G,Beretta GD,Berardi R,Scartozzi M

更新日期：2011-07-01 00:00:00

abstract：PURPOSE:This prospective multicenter phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of S-1 monotherapy in elderly patients over 75 years of age, with unresectable advanced or recurrent gastric cancer. METHODS:Patients had measurable or evaluable lesions according to the Japanes...

journal_title：Cancer chemotherapy and pharmacology

authors： Koizumi W,Akiya T,Sato A,Sakuyama T,Sasaki E,Tomidokoro T,Hamada T,Fujimori M,Kikuchi Y,Shimada K,Mine T,Yamaguchi K,Sasaki T,Kurihara M

更新日期：2010-05-01 00:00:00

abstract：:We studied the release of histamine elicited by some antineoplastic drugs in rat pleural and peritoneal mast cells. The drugs tested included the antibiotic mitomycin; the anthracyclines daunorubicin, doxorubicin, and epirubicin; the glycopeptide bleomycin; the chromopeptide dactinomycin; the platinum coordination com...

journal_title：Cancer chemotherapy and pharmacology

authors： Botana LM,Arnaez E,Vieytes MR,Alfonso A,Louzao MC

更新日期：1992-01-01 00:00:00

abstract：:A simple fluorescent microscopic method demonstrated that adriamycin was distributed in two cellular compartments of living rat colon cancer cells. Adriamycin accumulated slowly in cytoplasmic granules, probably lysosomes, where it persisted long after the drug was removed from the medium. On the other hand, adriamyci...

journal_title：Cancer chemotherapy and pharmacology

authors： Chauffert B,Martin F,Caignard A,Jeannin JF,Leclerc A

更新日期：1984-01-01 00:00:00

abstract：:The activity of CD437¿6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid¿, a relatively selective activator of RAR-gamma, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE...

journal_title：Cancer chemotherapy and pharmacology

authors： Langdon SP,Rabiasz GJ,Ritchie AA,Reichert U,Buchan P,Miller WR,Smyth JF

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

更新日期：2014-07-01 00:00:00

abstract：PURPOSE:Cytotoxic chemotherapy has been used to treat patients with metastatic colorectal cancer with limited success. Therefore novel chemotherapeutic approaches are needed. Based on encouraging preclinical data, there has been an interest in developing derivatives of butyrate as clinically applicable agents. The purp...

journal_title：Cancer chemotherapy and pharmacology

authors： Feinman R,Clarke KO,Harrison LE

更新日期：2002-01-01 00:00:00

abstract：:The present paper reviews several studies performed between 1977 and 1986 in Singapore on the 10-year survival outcome of treatment for stage I and II hepatocellular carcinoma (HCC). Of 801 HCC patients evaluated, only 2 survivors (0.3%) remained in complete remission for 13 and 14 years, respectively. One had receive...

journal_title：Cancer chemotherapy and pharmacology

authors： Oon CJ

更新日期：1992-01-01 00:00:00

abstract：:This report describes the physicochemical and pharmacokinetic parameters of seven chlorambucil esters, which were compared with those of chlorambucil. These esters were designed as chlorambucil prodrugs to increase the brain penetration and concentration vs time profile of chlorambucil within the CNS for potential tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Genka S,Daly EM,Sweeney DJ,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：:NQO1 is a reductive enzyme that is important for the activation of many bioreductive agents and is a target for an enzyme-directed approach to cancer therapy. It can be selectively induced in many tumor types by a number of compounds including dimethyl fumarate and sulforaphane. Mitomycin C is a bioreductive agent tha...

journal_title：Cancer chemotherapy and pharmacology

authors： Digby T,Leith MK,Thliveris JA,Begleiter A

更新日期：2005-09-01 00:00:00

abstract：PURPOSE:Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (>60 years) would be reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Owzar K,Lewis LD,Jiang C,Holleran JL,Christner SM,Blum W,Devine S,Kolitz JE,Linker C,Vij R,Alyea EP,Larson RA,Ratain MJ,Egorin MJ

更新日期：2014-11-01 00:00:00

abstract：:The primary development of clinical resistance to 1-beta-D-arabinofuranosyl cytosine (ara-C) in leukemic blast cells is expressed as decreased cellular concentrations of its active anabolite. Correlations exist between the cellular concentrations of 1-beta-D-arabinofuranosyl cytosine 5'-triphosphate (ara-CTP) in leuke...

journal_title：Cancer chemotherapy and pharmacology

authors： Avramis VI,Mecum RA,Nyce J,Steele DA,Holcenberg JS

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 human ovarian carcinoma cells....

journal_title：Cancer chemotherapy and pharmacology

authors： Varma R,Hector S,Greco WR,Clark K,Hawthorn L,Porter C,Pendyala L

更新日期：2007-05-01 00:00:00

abstract：:Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol i...

journal_title：Cancer chemotherapy and pharmacology

authors： Gangemi RM,Tiso M,Marchetti C,Severi AB,Fabbi M

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To assess the effect of elotuzumab on corrected QT (QTc) intervals and cardiac safety. METHODS:Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Passey C,Darbenzio R,Jou YM,Lynch M,Gupta M

更新日期：2016-12-01 00:00:00